Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Show more
1111 Kane Concourse, Bay Harbor Islands, FL, 33154, United States
Start AI Chat
Market Cap
883.4K
52 Wk Range
$0.15 - $0.97
Previous Close
$0.28
Open
$0.28
Volume
2,683
Day Range
$0.23 - $0.28
Enterprise Value
-2.826M
Cash
3.709M
Avg Qtr Burn
N/A
Insider Ownership
21.90%
Institutional Own.
7.26%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
IV Tramadol Details Pain, Post operative acute pain | Phase 3 Initiation | |
BAER-101 Details Anxiety Disorders, Epilepsy | Phase 2a Initiation | |
AJ201 Details Huntington's disease, Spinal and bulbar muscular atrophy , Spinocerebellar Ataxia, Kennedy's Disease | Phase 1/2 Update |